First trials test targeting of α-synuclein for Parkinson disease

被引：5
|
作者：
Kalia, Lorraine, V [1 ,2 ,3 ,4 ]
机构：
[1] Univ Toronto, Dept Med, Div Neurol, Toronto, ON, Canada
[2] Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON, Canada
[3] Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON, Canada
[4] Univ Hlth Network, Krembil Res Inst, Toronto, ON, Canada
来源：
NATURE REVIEWS NEUROLOGY | 2022年 / 18卷 / 12期
关键词：
D O I：
10.1038/s41582-022-00726-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
In the first two phase II trials of therapies that target alpha-synuclein to treat Parkinson disease, the primary endpoints were not met. However, the limitations of these studies need to be addressed in future trials and alternative approaches to targeting alpha-synuclein should be pursued before alpha-synuclein is discounted as a target.
引用
收藏
页码：703 / 704
页数：2
相关论文
共 50 条
  • [21] Parkinson's Disease: A Nanotheranostic Approach Targeting Alpha-Synuclein Aggregation
    Zoey, Fong LaiGuan
    Palanivel, Mathangi
    Padmanabhan, Parasuraman
    Gulyas, Balazs
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [22] Targeting α-Synuclein in Parkinson's Disease by Induced Pluripotent Stem Cell Models
    Spathopoulou, Angeliki
    Edenhofer, Frank
    Fellner, Lisa
    FRONTIERS IN NEUROLOGY, 2022, 12
  • [23] A monoclonal antibody targeting misfolded α-synuclein has therapeutic potential in Parkinson disease
    Heather Wood
    Nature Reviews Neurology, 2014, 10 (8) : 426 - 426
  • [24] Plant Extracts and Phytochemicals Targeting α-Synuclein Aggregation in Parkinson's Disease Models
    Javed, Hayate
    Meeran, Mohamed Fizur Nagoor
    Azimullah, Sheikh
    Adem, Abdu
    Sadek, Bassem
    Ojha, Shreesh Kumar
    FRONTIERS IN PHARMACOLOGY, 2019, 9
  • [25] Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
    Menon, Sindhu
    Armstrong, Sabrina
    Hamzeh, Amir
    Visanji, Naomi P.
    Sardi, Sergio Pablo
    Tandon, Anurag
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [26] Targeting α-synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease
    Haque, Md Ezazul
    Akther, Mahbuba
    Azam, Shofiul
    Kim, In-Su
    Lin, Yuxi
    Lee, Young-Ho
    Choi, Dong-Kug
    BRITISH JOURNAL OF PHARMACOLOGY, 2022, 179 (01) : 23 - 45
  • [27] First therapy targeting Parkinson's proteins enters clinical trials
    Dolgin, Elie
    NATURE MEDICINE, 2012, 18 (07) : 992 - 993
  • [28] First therapy targeting Parkinson's proteins enters clinical trials
    Elie Dolgin
    Nature Medicine, 2012, 18 : 992 - 993
  • [29] Targeting -Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics
    Savitt, Daniel
    Jankovic, Joseph
    DRUGS, 2019, 79 (08) : 797 - 810
  • [30] Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics
    Daniel Savitt
    Joseph Jankovic
    Drugs, 2019, 79 : 797 - 810
12345